SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-026094
Filing Date
2024-05-15
Accepted
2024-05-15 07:15:45
Documents
17
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20029167_8k.htm   iXBRL 8-K 40172
2 EXHIBIT 10.1 ef20029167_ex10-1.htm EX-10.1 73201
3 EXHIBIT 99.1 ef20029167_ex99-1.htm EX-99.1 146517
7 image00001.jpg GRAPHIC 2577
8 image00003.jpg GRAPHIC 2252
  Complete submission text file 0001140361-24-026094.txt   440236

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA atai-20240514.xsd EX-101.SCH 3856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20240514_lab.xml EX-101.LAB 22690
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20240514_pre.xml EX-101.PRE 16546
21 EXTRACTED XBRL INSTANCE DOCUMENT ef20029167_8k_htm.xml XML 4213
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 24947132
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)